30th anniversary
annual meeting & expo
November 19-23, 2024
Vancouver
British Columbia, Canada
AMP
2024
When cancer is diagnosed, finding treatment options
is the top priority.
is the top priority.
Booth 1301
Paul Wharton's Story
Paul Wharton's journey is a powerful testament to the transformative impact of advanced genomic testing in cancer treatment. Initially diagnosed with stage 2 kidney cancer, Paul underwent surgery and was told he was cured.
However, just six months later, he faced a devastating stage 4 diagnosis with diffuse metastatic tumors throughout his body. Conventional treatments offered little hope, and his prognosis was grim. It wasn't until a persistent friend convinced him to undergo genetic testing that a new path emerged.
The test revealed the presence of the PBMR1 biomarker, indicating that his cancer could respond to a specific immunotherapy called Nervy (Ipilimumab). This personalized treatment approach not only extended his life but ultimately led to him becoming cancer-free since November 2018.
Inspired by stories like Paul's, GoPath Diagnostics developed the OncoTarget Series—a comprehensive genomic profiling solution designed to identify targeted therapies for advanced cancers. By analyzing the unique genetic makeup of each patient's tumor, OncoTarget empowers physicians with actionable information to consider the most effective treatments and anticipate resistance to therapies.
Inspired by stories like Paul's, GoPath Diagnostics developed the OncoTarget Series—a comprehensive genomic profiling solution designed to identify targeted therapies for advanced cancers. By analyzing the unique genetic makeup of each patient's tumor, OncoTarget empowers physicians with actionable information to consider the most effective treatments and anticipate resistance to therapies.
OncoTarget®500
Comprehensive Genomic Profiling Panel
- Provides a thorough analysis of 500 cancer-related genes to help inform personalized cancer treatment decisions.
- Includes testing for tumor mutation burden (TMB) and microsatellite instability (MSI) to offer a molecular profile of the tumor.
- Delivers key biomarker data that can guide the selection of targeted therapies for improved patient outcomes.
- Results are available within 7-10 business days, allowing for timely and informed clinical decisions.
OncoTarget® Myeloid68
An NGS-Based Test for Myeloid Leukemia
- Myeloid68 covers mutations in 68 genes associated with myeloid malignancies to provide a detailed genetic profile.
- Helps in assessing prognosis by identifying mutations linked to disease progression and treatment responses.
- Identifies actionable mutations that can inform personalized treatment strategies for patients with myeloid cancers.
- Receive results within 7-10 business days, enabling faster decision-making for patient management.
OncoCore™
Because Waiting Shouldn't Be Part
of Your Oncology Plan
of Your Oncology Plan
- Created for fast access to actionable precision oncology, OncoCore is an advanced 32-gene NGS panel that uses targeted amplicon sequencing to analyze both DNA and RNA.
- Incorporates microfluidic devices to achieve full automation and provides results within a rapid 3-4 day turnaround.
- Detects all clinically significant single nucleotide variants (SNVs), Insertions and deletions (InDels), gene fusions, and microsatellite instability (MSI).
- This swift processing provides clinicians with essential, timely data to inform immunotherapy treatment decisions for their patients.
OncoTracking™
Minimal Residual Disease (MRD)
- OncoTracking is a highly sensitive monitoring tool that utilizes liquid biopsy to screen for ctDNA, allowing for the detection of cancer recurrence potentially months before it is detectable with traditional imaging methods
- OncoTracking begins with next-generation sequencing of a tissue sample to identify biomarkers that are unique to the tumor.
- Through monitoring for changes in the amount of ctDNA present, OncoTracking can determine tumor response to therapies.
Begin Your Journey
Our team is ready to get you started.
© GoPath Global, Inc. 2024 All rights reserved
Booth 1301